Undersøgelse af BDTX-1535 hos deltagere med glioblastom eller ikke-småcellet lungekræft
Et fase 1-studie til vurdering af BDTX-1535, en oral EGFR-hæmmer, hos deltagere med glioblastom eller ikke-småcellet lungekræft
BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of silevertinib (BDTX-1535). The study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) with non-classical or acquired epidermal growth factor receptor (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2), or glioblastoma (GBM) expressing EGFR alterations (Phase 1 only). All patients will self-administer silevertinib (BDTX-1535) monotherapy by mouth in 21-day cycles.
Phase 1 enrollment is now complete. Phase 2 is currently ongoing.
Studieoversigt
Status
Status
Betingelser
Betingelser
- Ikke-småcellet lungekræft
- NSCLC
- Metastatisk lungekræft
- Metastatisk lunge ikke-småcellet karcinom
- EGF-R positiv ikke-småcellet lungekræft
- Avanceret lungekarcinom
- EGFR-TKI resistent mutation
- Avanceret ikke-småcellet planocellulær lungekræft
- Epidermal vækstfaktorreceptor C797S
- Epidermal vækstfaktorreceptor G719X
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: BDTX Clinical Trial Navigation Service
- Telefonnummer: (866) 955-4397
- E-mail: blackdiamondtx@careboxhealth.com
Studiesteder
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 4E6
- Rekruttering
- BC Cancer Vancouver
-
Kontakt:
- Vishaldeep Sidhu
- Telefonnummer: 236-994-8251
- E-mail: ClinicalTrialsHelp@bccancer.bc.ca
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1X5
- Rekruttering
- The Princess Margaret Cancer Centre
-
Kontakt:
- Tuhina Paul
- Telefonnummer: 416-946-4501 x 7890
- E-mail: Tuhina.Paul@uhn.ca
-
-
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35294
- Rekruttering
- University of Alabama
-
Kontakt:
- Anna Wilbanks
- Telefonnummer: 205-934-6454
- E-mail: annaburton@uabmc.edu
-
-
Arizona
-
Gilbert, Arizona, Forenede Stater, 85234
- Rekruttering
- Banner MD Anderson Cancer Center
-
Kontakt:
- Brandi Luzania
- Telefonnummer: 480-256-5488
- E-mail: Brandi.Luzania@bannerhealth.com
-
-
California
-
Irvine, California, Forenede Stater, 92618
- Rekruttering
- City of Hope Orange County Lennar Foundation Cancer Center
-
Kontakt:
- Telefonnummer: 626-218-1133
-
Kontakt:
- Diana Patterson
- Telefonnummer: 949-671-4763
-
Los Angeles, California, Forenede Stater, 90048
- Rekruttering
- Cedars Sinai Medical Center
-
Kontakt:
- Garret Crook
- Telefonnummer: 424-314-0745
- E-mail: Garrett.Crook@cshs.org
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forenede Stater, 20016
- Rekruttering
- Sibley Memorial Hospital Johns Hopkins Medicine
-
Kontakt:
- Judith Lawrence
- Telefonnummer: 202-660-6500
- E-mail: sibleyoncresreferral@live.johnshopkins.edu
-
-
Florida
-
Jacksonville, Florida, Forenede Stater, 32224
- Rekruttering
- Mayo Clinic- Jacksonville
-
Kontakt:
- Yanyan Lou
- Telefonnummer: 855-776-0015
-
Miami, Florida, Forenede Stater, 33176
- Rekruttering
- Miami Cancer Institute - Baptist Health South Florida
-
Kontakt:
- Xiaoou Pan
- Telefonnummer: 785-594-7856
- E-mail: Xiaoou.pan@baptisthealth.net
-
-
Hawaii
-
Honolulu, Hawaii, Forenede Stater, 96813
- Rekruttering
- UHP- University of Hawaii Cancer Center
-
Kontakt:
- Evan Wu, MD
- Telefonnummer: 808-586-3010
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60611
- Rekruttering
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University
-
Kontakt:
- E-mail: clinicaltrials@northwestern.edu
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02115
- Rekruttering
- Dana-Farber Cancer Institute
-
Kontakt:
- Dawn Bissessar
- Telefonnummer: 617-632-5119
- E-mail: dawn_bissessar@dfci.harvard.edu
-
-
Minnesota
-
Rochester, Minnesota, Forenede Stater, 55905
- Rekruttering
- Mayo Clinic- Rochester
-
Kontakt:
- Anastasios Dimou, MD
- Telefonnummer: 855-776-0015
-
-
New York
-
The Bronx, New York, Forenede Stater, 10461
- Rekruttering
- Montefiore Medical Center
-
Kontakt:
- Balazs Halmos, MD
- Telefonnummer: 718-405-8404
- E-mail: bahalmos@montefiore.org
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forenede Stater, 15232
- Rekruttering
- University of Pittsburgh Medical Center - Hillman Cancer Center
-
Kontakt:
- Jennifer Ruth
- E-mail: ruthj2@upmc.edu
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37203
- Rekruttering
- Tennessee Oncology
-
Kontakt:
- Melissa Johnson, MD
- Telefonnummer: 615-320-5090
- E-mail: melissa.johnson@scri.com
-
-
Virginia
-
Fairfax, Virginia, Forenede Stater, 22031
- Rekruttering
- Inova Schar Cancer Institute
-
Kontakt:
- Stephanie Van Bebber
- Telefonnummer: 571-472-0213
- E-mail: Stephanie.VanBebber@inova.org
-
Fairfax, Virginia, Forenede Stater, 22031
- Rekruttering
- Next Oncology
-
Kontakt:
- Rebecca Fisher
- E-mail: rfisher@nextoncology.com
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98109
- Rekruttering
- Fred Hutchinson Cancer Center/University of Washington
-
Kontakt:
- Sam Woodman
- Telefonnummer: 206-606-6346
- E-mail: swoodman@fredhutch.org
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Phase 2 Eligibility:
Key Inclusion Criteria Required for locally advanced or metastatic NSCLC:
-
Measurable disease by RECIST 1.1 criteria.
-
Adequate bone marrow or organ function.
-
Life expectancy of ≥ 3 months.
-
Sufficient performance status.
-
Confirmed NSCLC, without small cell lung cancer transformation with or without brain metastases.
-
Disease progression following or intolerance of standard of care (excluding patients in the treatment-naïve non-classical driver cohort):
- Cohort 1 (Non-Classical driver cohort): Advanced/metastatic NSCLC with a non-classical driver EGFR mutation (eg, G719X) following up to 2 lines of therapy with only 1 prior EGFR TKI regimen (third-generation preferred; other approved EGFR TKI acceptable).
- Cohort 2 (Acquired resistance C797S cohort): Advanced/metastatic NSCLC with the acquired resistance C797S EGFR mutation following up to 2 lines of therapy, including only one EGFR TKI, which must be a third generation EGFR TKI (eg, osimertinib).
- Cohort 3 and 4 (First-line non-classical driver cohort): Treatment-naïve advanced/metastatic NSCLC with a non-classical driver EGFR mutations (1 cycle of chemotherapy or immune checkpoint inhibitor are permitted). Patients with co-occurring L858R mutations and a non-classical mutation are eligible for inclusion.
-
Identification of one (or more) of the following EGFR mutations by Next Generation Sequencing (NGS) as determined by a local assay performed in a validated laboratory in the absence of other known resistance mutations (eg, T790M, MET):
- Non-classical driver EGFR mutations (eg, L861R, S768I, G719X).
- EGFR acquired resistance mutation (eg, C797S) to a 3rd generation EGFR TKI.
- For Phase 2, dose expansion, patients in Cohort 1 who received 3rd generation EGFR TKI (eg, osimertinib), the NGS report within 6 months prior to the start of Screening is acceptable. For patients in Cohort 2, the NGS report must be from the last disease progression on the immediate prior therapy. For patients in Cohort 3 and 4, the NGS report must be at the time of diagnosis.
Key Exclusion Criteria:
- Known resistant mutations in tumor tissue or by liquid biopsy (eg, T790M, MET).
- Received more than 1 EGFR TKI therapy (ie, erlotinib or gefitinib) for the treatment of metastatic or recurrent EGFR NSCLC.
- Any history of interstitial lung disease related to EGFR TKI use.
- Symptomatic or radiographic leptomeningeal disease.
- Symptomatic brain metastases or spinal cord compression requiring urgent clinical intervention.
- Unresolved toxicity from prior therapy.
- Significant cardiovascular disease.
- Major surgery within 4 weeks of study entry or planned during study.
- Ongoing or recent anticancer therapy or radiation therapy.
- Evidence of malignancy (other than study-specific malignancies) requiring active therapy within the next 2 years.
- Active hepatitis B or C infection and/or known human immunodeficiency virus (HIV) carrier.
- Poorly controlled gastrointestinal disorders.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Phase 1 Dose Escalation - Monotherapy (Recruitment Closed)
|
Silevertinib (BDTX-1535) is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.
Andre navne:
|
|
Eksperimentel: Phase 2 Cohort 1: NSCLC EGFR Non-Classical Driver Mutations (Recruitment Closed)
Advanced/metastatic NSCLC with a non-classical driver EGFR mutation following up to 2 lines of therapy with only 1 prior EGFR targeted regimen (third-generation preferred; other approved EGFR inhibitors acceptable) |
Silevertinib (BDTX-1535) is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.
Andre navne:
|
|
Eksperimentel: Phase 2 Cohort 2: NSCLC EGFR Acquired Resistance (C797S) Mutation (Recruitment Closed)
Advanced/metastatic NSCLC with the acquired resistance C797S EGFR mutation following up to 2 lines of therapy, including only 1 EGFR targeted regimen, which must be a third generation EGFR TKI (eg, osimertinib) |
Silevertinib (BDTX-1535) is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.
Andre navne:
|
|
Eksperimentel: Phase 2 Cohort 3: Treatment Naive NSCLC EGFR Non-Classical Driver Mutations (Recruitment Closed)
Treatment-naïve (first-line) advanced/metastatic NSCLC with a non-classical driver EGFR mutation (1 cycle of chemotherapy or immune checkpoint inhibitor are permitted). Patients with co-occurring L858R mutations and a non-classical mutation are eligible for inclusion. Silevertinib dose for Cohort 3 is 200 mg QD. |
Silevertinib (BDTX-1535) is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.
Andre navne:
|
|
Eksperimentel: Phase 2 Cohort 4: Treatment Naive NSCLC EGFR Non-Classical Driver Mutations at 150 mg QD Dose
Treatment-naïve (first-line) advanced/metastatic NSCLC with a non-classical driver EGFR mutation (1 cycle of chemotherapy or immune checkpoint inhibitor are permitted). Patients with co-occurring L858R mutations and a non-classical mutation are eligible for inclusion. Silevertinib dose for Cohort 4 is 150 mg QD. |
Silevertinib (BDTX-1535) is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Phase 1 Dose Escalation: To determine the maximum tolerated dose (MTD), if one exists, and the preliminary recommended Phase 2 dose(s) (RP2D[s]) of silevertinib (BDTX-1535)
Tidsramme: The first treatment 21-day cycle (Cycle 1)
|
Dose-limiting toxicities (DLTs) in Cycle 1 |
The first treatment 21-day cycle (Cycle 1)
|
|
Phase 2 (Cohorts 1, 2, and 3): To assess antitumor efficacy of silevertinib (BDTX-1535)
Tidsramme: Day 1 every 2 cycles starting on Cycle 3 Day 1 to study completion, approximately 1 year (each cycle is 21 days)
|
Objective response rate (ORR) as assessed by Investigator using RECIST version 1.1 |
Day 1 every 2 cycles starting on Cycle 3 Day 1 to study completion, approximately 1 year (each cycle is 21 days)
|
|
Phase 2 Cohort 4 Only: To assess the safety and tolerability of silevertinib at the 150 mg QD dose
Tidsramme: Through study completion, approximately 1 year
|
Treatment-emergent adverse events |
Through study completion, approximately 1 year
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Fase 2: At vurdere progressionsfri overlevelse med RECIST version 1.1
Tidsramme: Dag 1 hver anden cyklus starter ved cyklus 3 Dag 1 til studieafslutning, cirka 1 år (hver cyklus er 21 dage)
|
Dag 1 hver anden cyklus starter ved cyklus 3 Dag 1 til studieafslutning, cirka 1 år (hver cyklus er 21 dage)
|
|
|
Fase 1: At vurdere den foreløbige antitumoraktivitet af Silevertinib (BDTX-1535) ved objektiv respons som vurderet af RECIST version 1.1 (for patienter med NSCLC) eller responsvurdering i neuro-onkologi (RANO) (for patienter med GBM)
Tidsramme: Dag 1 hver 2. cyklus, der starter på cyklus 3 dag 1 for at studere færdiggørelse, cirka 1 år (hver cyklus er 21 dage)
|
Dag 1 hver 2. cyklus, der starter på cyklus 3 dag 1 for at studere færdiggørelse, cirka 1 år (hver cyklus er 21 dage)
|
|
|
Phase 2 Cohort 4 Only: To assess antitumor efficacy of silevertinib (BDTX-1535)
Tidsramme: Day 1 every 2 cycles starting on Cycle 3 Day 1 to study completion, approximately 1 year (each cycle is 21 days)
|
Objective response rate (ORR) as assessed by Investigator using RECIST version 1.1 |
Day 1 every 2 cycles starting on Cycle 3 Day 1 to study completion, approximately 1 year (each cycle is 21 days)
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Black Diamond Therapeutics, Black Diamond Therapeutics
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
- EGFR-hæmmer
- hjernemetastaser
- EGFR L858R
- CNS-metastaser
- intrakraniel sygdom
- EGFR ændringer
- metastaser i centralnervesystemet
- EGFR Exon 19 del
- indre modstand NSCLC EGFR
- erhvervet resistens NSCLC EGFR
- ualmindelige NSCLC EGFR-mutationer
- C797S erhvervede resistens EGFR-mutation
- ikke-klassiske NSCLC EGFR-mutationer
- klassiske NSCLC EGFR-mutationer
- Anden-site EGFR mutation
- EGFR PACC NSCLC mutationer
- EGFR E709A/G/K/Q/V
- EGFR E709_T710delinsD/T
- EGFR G719A/C/D/R/S
- EGFR G724S
- EGFR L718Q/V
- EGFR L747S/P, L747_A750delinsP, L747_P753delinsS
Yderligere relevante MeSH-vilkår
- Hjernesygdomme
- Sygdomme i centralnervesystemet
- Sygdomme i nervesystemet
- Neoplasmer efter sted
- Neoplasmer
- Luftvejssygdomme
- Lungesygdomme
- Neoplasmer i luftvejene
- Thoracale neoplasmer
- Neoplasmer i nervesystemet
- Karcinom, bronkogent
- Bronkiale neoplasmer
- Neoplasmer i centralnervesystemet
- Lungeneoplasmer
- Karcinom, ikke-småcellet lunge
- Neoplasmer i hjernen
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- BDTX-1535-101
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .